Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.75 |
| ▸ | SRC | P12931 | 7/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | BCR | P11274 | 7/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | PRKACG | P22612 | 1/20 | 0.59 |
| ▸ | PRKACB | P22694 | 1/20 | 0.59 |
| ▸ | ABL2 | P42684 | 1/20 | 0.57 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4000628 | 0.92 | ABL1 (0.69) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL1762 | 0.86 | ABL1 (1.00) | ABL1SRCPDGFRBPDGFRASMN1; SMN2 | |
| SCHEMBL4003528 | 0.85 | ABL1 (0.58) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL27771353 | 0.84 | ABL1 (0.59) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL5463021 | 0.84 | ABL1 (0.66) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL4002797 | 0.83 | ABL1 (0.74) | ABL1SRCPDGFRBPDGFRABCR | |
| SCHEMBL4001863 | 0.83 | MAPT (0.67) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL4002108 | 0.81 | ABL1 (0.71) | ABL1SRCPDGFRBPDGFRASMN1; SMN2 | |
| SCHEMBL4003048 | 0.81 | ABL1 (0.60) | ABL1SRCPDGFRBPDGFRAMAPT | |
| SCHEMBL3523274 | 0.79 | ABL1 (0.65) | ABL1SRCPDGFRBPDGFRASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440663-B2 | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2172460-A1 | Compositions useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1562911-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-01-06 | — | — | EP | disclosed |
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007089768-A2 | 4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EXELIXIS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| EP-1562911-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-29 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298830-A1 | 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | ABL1 14/4885SRC 225/4885PDGFRB 23/4885 |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | JAK1, JAK2, JAK3 | ABL1 6/4885SRC 81/4885PDGFRB 1028/4885 |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | ABL1 131/4885SRC 146/4885PDGFRB 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.